Navigation Links
Bovie Medical Corporation Announces Fiscal Year 2012 Financial Results
Date:4/1/2013

MELVILLE, N.Y., April 1, 2013 /PRNewswire/ -- Bovie Medical Corporation (the "Company") (NYSE Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced its financial results for the year ended December 31, 2012 and fourth quarter.

Revenues for the year ended December 31, 2012 increased 8.9% to $27.7 million versus $25.4 million for the comparable period the prior year. Net income for FY 2012 totaled $617,000 or $.03 per diluted share compared to $109,000 or $.01 diluted share in the same period last year. Higher sales resulted from increased general demand in all segments of Bovie's business.

Revenues for the quarter ended December 31, 2012 were $6.8 million versus $6.2 million in the comparable period last year; resulting in net income of $285,000 or $.02 per diluted share after the effects of adjusting the quarterly tax provision and gain on the valuation of our warrant liability.  For the fourth quarter of FY 2011 the Company reported a loss of $(875,000) or $(.05) per diluted share, which included a recognized $1,591,000 expense for the transfer of inventory and intellectual property related to a legal settlement.

In a March 2011 news release, mention was made of an anticipated developmental and manufacturing agreement with a large medical device company.  Due to modified specifications yet to be finalized, discussions are continuing.

J-Plasma™ NewsOn Monday, March 25 in Las Vegas, NV the Company completed the second in a series of surgical courses designed to introduce J-Plasma™ to surgeons, clinicians and sales representatives from across the U.S.  The first course was held in Nashville, TN on Thursday, March 21st.  Both went smoothly with excellent results.  The courses are given to optimize the surgeons experience allowing the return to their respective practices and hospitals with a full understanding of J-Plasma™ and its potential.  Judging from surgeon attendee responses it is expected that a high percentage of these surgeons will commit to the use of J-Plasma™.

Royce T. Adkins , M.D., well-known researcher and gynecology surgeon, who lectured the Nashville surgical course, stated: "These courses allow surgeons from multiple disciplines to familiarize with J-Plasma™, hence becoming quickly proficient in a safe environment and, importantly, provide a better patient outcome."

Jeff Rencher , V.P. of Sales for Surgical Production stated:  "Our representatives have done an outstanding job in introducing J-Plasma™ to large parts of the U.S.  The high level of interest resulting from these courses clearly demonstrates J-Plasma's™ broadening appeal."

In recent news, the U.S. Patent and Trademark Office issued a notification that a patent will issue for Bovie's "Electrosurgical Device to Generate a Plasma Stream."  The issue date is April 2, 2013.  Currently, there are five patents issued on J-Plasma™ and another six pending.

In other news, management is pleased to report that on February 21, 2013, Bovie Medical's President and Chief Sales and Marketing Officer, J. Robert Saron was inducted into the Medical Distribution Hall of Fame in Atlanta Georgia.  Mr. Saron is one of only three individuals in the medical device industry to have received the Industry Award of Distinction from the Health Industry Distributors Association, The Leonard Berke Achievement Award from the Healthcare Manufacturers Management Council and be inducted into the Medical Distribution Hall of Fame.

Cautionary Note on Forward-Looking StatementsCertain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws.  Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected.  Many of these factors are beyond the Company's ability to control or predict.  Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company's filings with the Securities and Exchange Commission including the Company's Report on Form 10‑K for the year ended December 31, 2012.  For forward-looking statements in this new release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

For further information about the Company's current and new products, please refer to the Investor Relations section of Bovie's website www.boviemed.com.

For further information contact:

Bovie Medical Investor Relations and Shareholder Information

Joseph M. Vazquez III
Phone: (800) 448-7097
Email: infinityglobalconsulting@gmail.comBovie Medical Corporation
Condensed Statements of Operations
For the Three and twelve-month Periods

(in thousands, except for per share amounts)Three Months Ended
December 31 (Unaudited)

Year Ended

December 312012

2011

2012

2011Revenues

$6,827

$6,158

$27,671

$25,411Cost of Sales

4,040

3,512

16,338

14,680Gross Profit

2,787

2,646

11,333

10,731Gain (loss) on legal settlement

--

--

--

750Costs & Expenses

2,659

2,457

10,287

9,908Legal Settlement

--

1,591

--

1,591Income (loss) from operations

128

(1,402)

1,046

(18)Other income (expense)Interest (net of expense)

(58)

(96)

(232)

(237)Other Gain (loss)

128

106

20

287Income (loss) before income taxes

198

(1,392)

834

32Benefit (provision) for deferred income taxes

87

517

(217)

77Net Income (loss)

$285

(875)

$617

$109EPS (loss) Basic

0.02

(0.05)

$0.04

$0.01EPS (loss) Diluted

0.02

(0.05)

$0.03

$0.01Weighted average shares Outstanding-Basic

17,638

17,614

17,631

17,597Weighted average shares adjusted for dilutive securities

17,830

17,614

17,787

17,669
'/>"/>

SOURCE Bovie Medical Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vasomedical Announces Financial Results for the Fourth Quarter and Year Ended 2012
2. The Guide to Distributors of Medical Equipment & Supplies Worldwide 2012
3. Varian Medical Systems Appoints Deepak "Dee" Khuntia M.D. Vice President of Medical Affairs
4. Medical Marijuana Dispensary Open In Eloy, Arizona!!!
5. Doing Business in China: Research on Chinese Good Manufacturing Practice Regulations for Medical Devices
6. U.S. Enterprise Medical Image Archiving Market
7. Anne Arundel Medical Center to Improve Patient Safety with Superbug-Slaying Robot TRU-D
8. Medical Imaging Markets
9. US FDA Inspection Reveals Excite Medical Does Not Own 510(k) Clearances for any DRX System
10. IFHP Study Reveals Disparity In Medical Costs Around The Globe
11. Orthopedic Practices Choose Medicalbillersandcoders.coms Orthopedic Billing Solutions for Their Cash Flow Problems!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider ... and other difficult to transfect cells, announces its launch of the PluriQ™ G9™ ... Editing System is a complete system for culturing and transfecting human pluripotent ...
(Date:6/24/2016)... ... June 24, 2016 , ... Southern Illinois University ... co-chairs for the Illinois State Dental Society (ISDS) Foundation’s Mission of Mercy (MOM). ... Convention Center in Collinsville. , They expect to treat approximately 2,000 ...
Breaking Medicine News(10 mins):